PLAUR and neoplasm: These findings suggest the co-targeting of LRP/uPAR by nanoparticle-drug delivery into breast cancer patient derived xenograft tumors, thus resulting in remarkable tumor growth inhibition (Miller-Kleinhenz et al., 2018).